Instem logo

INS - Instem Share Price

577.5p 27.5  5.0%

Last Trade - 10:31am

Small Cap
Market Cap £114.8m
Enterprise Value £109.1m
Revenue £28.1m
Position in Universe 974th / 1809
Unlock INS Revenue
Relative Strength (%)
1m +6.44%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.14%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
13.4 16.3 18.3 21.1 22.7 25.7 28.9 32.5 +13.9%
-66.4 +107.4 +4.5 +36.9 +100.3 -28.6 +118.4 -1.00
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Instem PLCrevenues increased 20% to £14M. Net income increased from£329K to £1.6M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Net income benefited from Operating expensesdecrease of 69% to £3M (expense), Foreign exchange lossesdecrease from £82K (expense) to £0K, Amortization in SGAdecrease of 17% to £310K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for INS
Graphical History


INS Revenue Unlock INS Revenue

Net Income

INS Net Income Unlock INS Revenue

Normalised EPS

INS Normalised EPS Unlock INS Revenue

PE Ratio Range

INS PE Ratio Range Unlock INS Revenue

Dividend Yield Range

INS Dividend Yield Range Unlock INS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
INS EPS Forecasts Unlock INS Revenue
Profile Summary

Instem plc is a supplier of information technology (IT) applications to the early development healthcare market delivering solutions for data collection, management and analysis across the research and development continuum. The Company is engaged in Global Life Sciences operations. Its lead product suite, Provantis, is an application in the Early Development Safety Assessment (EDSA) market. The Provantis solution incorporates a suite of modules required for managing and recording EDSA studies, from receipt of the compound through to the automated assembly of statistical analyses and final reports. Its software allows scientific staff to collect, analyze and share data across the organization and externally. It also offers ALPHADAS, an early phase clinical software solution. The Company offers Centrus suite, which provides pre-built applications, as well as the ability to utilize a range of business intelligence and analysis tools.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 5, 2010
Public Since October 13, 2010
No. of Shareholders: n/a
No. of Employees: 268
Sector Technology
Industry Software & IT Services
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 20,873,829
Free Float (0.0%)
Eligible for
INS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for INS
Upcoming Events for INS
Frequently Asked Questions for Instem
What is the Instem share price?

As of 10:31am, shares in Instem are trading at 577.5p, giving the company a market capitalisation of £114.8m. This share price information is delayed by 15 minutes.

How has the Instem share price performed this year?

Shares in Instem are currently trading at 577.5p and the price has moved by 7.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Instem price has moved by 2.41% over the past year.

What are the analyst and broker recommendations for Instem?

Of the analysts with advisory recommendations for Instem, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Instem is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Instem next release its financial results?

Instem is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Instem dividend yield?

Instem does not currently pay a dividend.

Does Instem pay a dividend?

Instem does not currently pay a dividend.

When does Instem next pay dividends?

Instem does not currently pay a dividend.

How do I buy Instem shares?

To buy shares in Instem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Instem?

Shares in Instem are currently trading at 577.5p, giving the company a market capitalisation of £114.8m.

Where are Instem shares listed? Where are Instem shares listed?

Here are the trading details for Instem:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: INS
What kind of share is Instem?

Based on an overall assessment of its quality, value and momentum, Instem is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Instem share price forecast 2021?

We were not able to load any forecast data for Instem.

How can I tell whether the Instem share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Instem. Over the past six months, the relative strength of its shares against the market has been -6.32%. At the current price of 577.5p, shares in Instem are trading at 13.12% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Instem PE Ratio?

The Instem PE ratio based on its reported earnings over the past 12 months is 35.19. The shares are currently trading at 577.5p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Instem?

Instem's management team is headed by:

David Gare - NEC
Philip Reason - CEO
David Sherwin - NED
Michael McGoun - NID
Nigel Goldsmith - CFO
MaryBeth Thompson - COO
Who are the major shareholders of Instem?

Here are the top five shareholders of Instem based on the size of their shareholding:

Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 9.65% (2.01m shares)
Liontrust Asset Management PLC Investment Advisor/Hedge Fund
Percentage owned: 8.37% (1.75m shares)
Liontrust UK Smaller Companies Fund Mutual Fund
Percentage owned: 7.49% (1.56m shares)
Aberdeen Standard Investments (Edinburgh) Investment Advisor
Percentage owned: 6.33% (1.32m shares)
Canaccord Genuity Wealth Management Investment Advisor/Hedge Fund
Percentage owned: 5.87% (1.23m shares)
Similar to INS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.